MANNHEIM, Germany, Feb. 1, 2011 /PRNewswire/ -- An innovative diabetes management concept including structured self-monitoring of blood glucose (SMBG), data visualization, pattern analysis and derived therapy adjustments can significantly reduce HbA1c values, improve glycemic control and enhance patients' quality of life. These are the key findings of the 12-month data from the Structured Testing Protocol (STeP) Study, newly published in Diabetes Care.(1) Self-monitoring of blood glucose (SMBG) is a well-established element of therapy management for people with type 1 or type 2 diabetes on insulin therapy.(2,3) However, there have been controversial views on the question of whether regular SMBG is similarly beneficial for non-insulin treated people with type 2 diabetes. (4,5,6,7) To gain new insights on this subject, the STeP Study was performed: A prospective, cluster-randomized, multi-center clinical trial, which examined the impact of structured SMBG upon glycemic control in 483 non-insulin treated people with type 2 diabetes who evidenced poor glycemic control (HbA1c greater than or equal to 7.5%) at baseline. The results provide new and significant evidence on its effectiveness.
The study design - usual diabetes care vs. structured diabetes managementParticipants were recruited from various primary care practices across the eastern United States. Practices were randomly assigned to an active control group (ACG; n=227) or to a structured testing group (STG; n=256). Duration of the study was 12 months, and evaluations of clinical parameters were performed at baseline and during scheduled visits at months 1, 3, 6, 9 and 12. During the visits, healthcare professionals obtained relevant laboratory data, and all participants completed questionnaires relating to their quality of life. Patients in the ACG received enhanced usual care, complying with U.S. standard of care recommendations. STG patients received t
|SOURCE Roche Diabetes Care|
Copyright©2010 PR Newswire.
All rights reserved